← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Anidulafungin

FDA approved · Rx

Echinocandin antifungal

Also known as: Eraxis

Evidence score
91/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 43 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Anidulafungin, sold as Eraxis, is a semisynthetic lipopeptide antifungal in the echinocandin class. It works by blocking the enzyme 1,3-beta-D-glucan synthase, which fungi need to build their cell walls, leading to weakened walls and fungal cell death.

What the evidence shows

Automatic summaryHuman trials

It is FDA approved for candidemia and certain other invasive Candida infections, including intra-abdominal abscess and peritonitis, as well as esophageal candidiasis, and is supported by 43 registered human trials reaching Phase 4 and a large published literature. Its use outside these approved fungal infections is less well established.

Key facts

Molecular formula
C58H73N7O17
Molecular weight
1140.2 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

43registered studies
Phase 4most advanced phase
27completed (sample)
0recruiting (sample)

Anidulafungin Pharmacokinetics in Intensive Care Unit Patients

UnknownNCT01438216

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

Phase 3CompletedNCT00058682

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3TerminatedNCT05178862

Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

TerminatedNCT01213823

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,423papers referencing Anidulafungin

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for <i>Candida</i> Species From 1997-2016.

Open Forum Infect Dis2019

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Clin Infect Dis2013

Anidulafungin versus fluconazole for invasive candidiasis.

N Engl J Med2007

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Haematologica2017

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.